The present invention relates to new substituted imidazotriazinones, processes for their preparation, and their use for the production of medicaments, in particular for improving perception, concentration power, learning power and/or memory power.
The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.
[EN] 5-ETHYL-IMIDAZO (5,1-F) (1,2,4,) TRIAZIN-4 (3H) -ONES AS PHOSPHODIESTERASE INHIBITORS<br/>[FR] 5-ETHYL-IMIDAZO(5,1-F)(1,2,4,)TRIAZIN-4(3H)-ONES COMME INHIBITEURS DE PHOSPHODIESTERASE
申请人:BAYER AG
公开号:WO2003093270A1
公开(公告)日:2003-11-13
The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.
5-ethyl-imidazo (5,1-F) (1,2,4,) triazin-4 (3h)-ones as phosphodiesterase inhibitors
申请人:Alonso-Alija Cristina
公开号:US20050272732A1
公开(公告)日:2005-12-08
The invention relates to novel 5-ethyl-imidazotriazinones, processes for their preparation and their use in medicaments, esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.
Imidazotriazines for use as phosphodiesterase inhibitors
申请人:——
公开号:US20040249148A1
公开(公告)日:2004-12-09
The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.